BridgeMD
A study to find how well REC-4881 works and how safe it is in participants with familial adenomatous polyposis (FAP)
EU CTIS ID: 2026-525282-50-00
What this study is testing
Part 1: To evaluate the pharmacokinetics (PK) of REC-4881 Part 2: To identify the Recommended Phase 2 Dose (RP2D) of REC-4881 To assess the safety and tolerability REC-4881 To evaluate the effect of REC-4881 on polyp burden
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients that: • are at least 18 years old. • have been diagnosed with FAP, which continues to affect the remaining portions of the bowels after surgery to remove all or part of the colon. • have a confirmed change (mutation) in the APC gene (for Part 2).
You likely can't join if
- Patient that: • has abnormal test results or a health problem that could make it unsafe to take part in the study. • has received radiation treatment to the lower belly (pelvic area) in the past. • have cancer in the stomach, duodenum, colon, rectum, or pouch at screening (Part 2). • have a large polyp that cannot be completely removed. • are currently receiving treatment for cancer of the lower belly or have taken certain medicines that may interfere with REC-4881 before joining the study.
The study team makes the final eligibility decision.
Where it's taking place
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.